TrialBritish journal of cancer2008

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.

K R Schønnemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.